Neonatal acetylcholinesterase inhibition by fasciculin 2 in rats: a model for the study of central nervous system development?

Fasciculin 2 (FAS), a potent acetylcholinesterase (AChE, EC 3.1.1.7) inhibitory peptide with affinity for the enzyme in the nanomolar range was utilized together with two other AChE inhibitors (Paroxon and BW284c51) to study the role of AChE in central nervous system development. When drugs were intracisternally injected at postnatal days 3 and 5, only FAS showed a significant inhibition of hippocampus and striatum AChE (39% and 77% inhibition, respectively). After FAS treatment, animals showed convulsive behaviour which was blocked by subcutaneous pretreatment with atropine sulfate (10 mg/kg). An assessment of developmental indices showed no alteration in neurological reflex maturation, motor behaviour or cell morphology. Body weight gain was significantly lower only in FAS-treated animals compared to controls during the preweaning period. To investigate the specificity of this effect a synthetic loop of FAS (showing no activity in vitro or in vivo) and oxidized FAS (showing a weak inhibition in vitro and no activity in vivo) were also intracisternally injected. Animals injected with the loop showed normal body weight development while those treated with oxidized FAS showed impairment in body weight. In conclusion, FAS was the most potent drug at inhibiting neonatal AChE in vivo without nonspecific brain damage. Impairment in body weight seems to be dependent on AChE involvement, although the possibility of a direct FAS effect is discussed. These results point to FAS intracisternal treatment as a useful in vivo model to study the role of AChE in the critical period of early postnatal central nervous system development.

Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats.

The acetylcholinesterase inhibitor peptide fasciculin (FAS) was bilaterally injected into the striatum of rats. Twenty-four hours after injection, animals showed a cataleptic syndrome that was potentiated by haloperidol (HAL). The catalepsy was significantly decreased by IP atropine. Biochemically, only an increase of the homovanillic acid in the striatum was found 24 h and 7 days after FAS treatment. Seven days after the intrastriatal FAS injection, there was no HAL potentiation of catalepsy, which was even lower than that of rats treated with IP HAL after intrastriatal injection of saline. Results are interpreted as showing the central role of the cholinergic system in the induction of catalepsy in the rat.

Biochemical and behavioral effects of intraseptal microinjection of fasciculin, an irreversible acetylcholinesterase inhibitor.

1. We examined the effect, in rats, of an intraseptal microinjection of fasciculin (FAS), an irreversible peptide acetylcholinesterase (AChE) inhibitor, on a) AChE activity measured in septum and hippocampus, b) 3H-quinuclidinyl benzylate (3H-QNB) and 3H-oxotremorine (3H-OXO) binding to hippocampal cholinergic muscarinic receptors, c) 3H-flunitrazepam (3H-FNZ) binding to hippocampal benzodiazepine receptors as a control for QNB and OXO binding, d) acquisition and retention in three different behavioral paradigms, i.e., water-finding (in which there is concomitant habituation to the apparatus), step-down inhibitory avoidance, and shuttle avoidance. 2. AChE activity in septum decreased 2 days (-66%) and 5 days (-48%) after FAS microinjection; a slight reduction (-35%) occurred in the dorsal hippocampus on day 2 (P less than 0.05; N = 6 per group); no changes in AChE activity were observed in ventral hippocampus on day 2 or day 5. 3. No changes in 3H-QNB, 3H-OXO, or 3H-FNZ binding constants were demonstrable in the hippocampus either 2 or 5 days after intraseptal FAS administration. 4. No changes in training or test session performance in any of the three behavioral situations were observed 2-3 days after the intraseptal microinjection of FAS. 5. The persistent inhibition of septal AChE caused by FAS microinjection into the septum is not sufficient to induce major changes either in hippocampal cholinergic muscarinic receptors, or in the learning or retention of behaviors regulated by the septum and/or hippocampus.

Biochemical and behavioral effects of intraseptal microinjection of fasciculin, an irreversible acetylcholinesterase inhibitor

We examined the effect, in rats, of an intraseptal microinjection of fasciculin (FAS), an irreversible peptide acetylcholinesterase (AChE) inhibitor, on a)AChE activity measured in septum and hippocampus, b)3H-quinuclidiny benzylate (3H-QNB) and 3H-oxotremorine (3H-OXO) binding to hippocampal cholinergic muscarinic receptors, c) 3H-flunitrazepan (3H-FNZ) binding to hippocampal benzodiazepine receptors as a control for QNB and OXO binding, d) acquisition and retention in three different behavioral paradigms, i. e., water-finding (in which there is concomitant habituation to be apparatus), step-down inhibitory avoidance, and shuttle avoidance. AChE activity in septum decreased 2 days (-66%) and 5 days (-48%) after FAS microinjection; a slight reduction (-35%) occurred in the dorsal hippocampus on day 2 (P<0.05; N=6 per group); no changes in AChE activity were observed in ventral hippocampus ion day 2 or day 5. No changes in 3H-QNB, 3H-OXO, or 3H-FNZ binding constants were demonstrable in the hippocampus either 2 or 5 days after intraseptal FAS adminstration. No changes in training or test session performance in any of the three behavioral situations were observed 2-3 days after the intraseptal microinjection of FAS. The persistent inhibition of septal AChE caused by FAS microinjection into the septum is not sufficient to induce major changes either in hippocampal cholinergic muscarinic receptors, or in the learning or retention of behaviors regulated by the septum and/or hippocampus

Neurochemical and behavioral correlates of unilateral striatal acetylcholinesterase inhibition by fasciculin in rats.

Fasciculin 2 (FAS) an anticholinesterase peptide isolated from the venom of the Green mamba (Dendroaspis angusticeps) was injected into the right striatum of albino rats (1.5 micrograms total amount). The inhibition of acetylcholinesterase (AChE) activity was 86 and 60% 24 h and 7 days after FAS injection, respectively. The treatment with apomorphine (APO) (2 mg/kg s.c.) 24 h after FAS provoked a moderate circling towards the lesioned side that was reverted by atropine (30 mg/kg i.p.). The same dose of APO 7 days after FAS, provoked an inconstant contralateral circling. Neither dopamine nor serotonin nor their metabolites were significantly affected 24 h or 7 days after FAS injection. Radioligand binding assays of dopamine, muscarinic and benzodiazepine receptors only showed a decrease of the density of the muscarinic ones 7 days after FAS. These results are interpreted as showing that the changes provoked by FAS would be compensated but the system would remain in an unsteady state only demonstrable after pharmacological challenge. The chronic down-regulation of muscarinic receptors would compensate the increased cholinergic activity and would therefore block its behavioral expression.

Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat.

The effects of neonatal intracisternal 6-hydroxydopamine (6-OHDA; 50 micrograms) treatment on striatal serotonin (5-HT) nerve terminals in rat have been characterized using histo- and neurochemical methods. The 6-OHDA lesion caused a 60% reduction of striatal dopamine (DA) concentration when analyzed in the adult stage, while 5-HT levels were increased by about 40% and 3H-5-HT uptake in vitro was increased by about 60%. Using computerized image analysis, a marked increase in 5-HT-like immunoreactive terminal density was found in both rostral (+200%) and caudal (+50%) striatum. Pretreatment with the DA uptake blocker amfolenic acid completely counteracted the 6-OHDA-induced alterations in both DA and 5-HT neurons in the striatum, while pretreatment with the noradrenaline uptake blocker desipramine had no significant effects. Regional analysis of 5-HT levels in the CNS after neonatal 6-OHDA treatment or the combined desipramine + 6-OHDA treatment showed no significant effect in any of the brain areas analyzed, apart from the observed 5-HT increase in striatum. It was furthermore observed that the striatal 5-hydroxyindoleacetic acid (5-HIAA)/5-HT ratio was decreased, while the 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio was increased following the 6-OHDA lesion, indicating compensatory mechanisms in turnover of transmitters. These alterations were completely reversed after pretreatment with amfolenic acid. The present results support the view that the 5-HT hyperinnervation following neonatal 6-OHDA treatment is a collateral sprouting response induced by lesioning of the striatal DA neurons.

Rat striatal acetylcholinesterase inhibition by fasciculin (a polypeptide from green mamba snake venom).

It has been shown that Fasciculins (FAS), polypeptides isolated from the venom of the green mamba Dendroaspis angusticeps, provoke a powerful inhibition of peripheral acetylcholinesterase (AChE). In the present study, 0.5 microliter of increasing concentrations (10-500 micrograms/ml) of FAS were injected into the striatum of rats. Micropunches taken 2 mm around the injection site showed 90% inhibition of AChE up to 24 h after FAS injection (500 micrograms/ml). AChE activity was about 50% of controls at the 7th day without apparent cell loss. Assessment of AChE activity in the whole striatum showed no inhibition. It is postulated that, due to this potent, localized and long-lasting central nervous system AChE inhibition, FAS could become a useful tool for the study of central cholinergic pathways.